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Abstract
Chagas Disease, caused by the protozoan Trypanosoma cruzi, is a major health and eco-
nomic problem in Latin America for which no vaccine or appropriate drugs for large-scale
public health interventions are yet available. Accurate diagnosis is essential for the early
identification and follow up of vector-borne cases and to prevent transmission of the disease
by way of blood transfusions and organ transplantation. Diagnosis is routinely performed
using serological methods, some of which require the production of parasite lysates, para-
site antigenic fractions or purified recombinant antigens. Although available serological
tests give satisfactory results, the production of reliable reagents remains laborious and
expensive. Short peptides spanning linear B-cell epitopes have proven ideal serodiagnostic
reagents in a wide range of diseases. Recently, we have conducted a large-scale screening
of T. cruzi linear B-cell epitopes using high-density peptide chips, leading to the identification
of several hundred novel sequence signatures associated to chronic Chagas Disease.
Here, we performed a serological assessment of 27 selected epitopes and of their use in a
novel multipeptide-based diagnostic method. A combination of 7 of these peptides were
finally evaluated in ELISA format against a panel of 199 sera samples (Chagas-positive and
negative, including sera from Leishmaniasis-positive subjects). The multipeptide formulation
displayed a high diagnostic performance, with a sensitivity of 96.3% and a specificity of
99.15%. Therefore, the use of synthetic peptides as diagnostic tools are an attractive alter-
native in Chagas’ disease diagnosis.
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Author summary
Chagas disease, caused by the parasite Trypanosoma cruzi, is a life-long and debilitating ill-
ness of major significance throughout Latin America, and an emergent threat to global
public health. Diagnostic tests are key tools to support disease surveillance, and to ulti-
mately help stop transmission of the parasite. However currently available diagnostic
methods have several limitations. Identification of novel biomarkers with improved diag-
nostic characteristics is a main priority. Recently, we conducted a large-scale screening
looking for new T. cruzi antigens using short peptides displayed on a solid support at
high-density. This led to the identification of several hundred novel antigenic epitopes. In
this work we validated the serodiagnostic performance of 27 of these against an extended
panel of human serum samples. Based on this analysis, we developed a proof-of-principle
multiplex diagnostic kit by combining different validated reactive peptides. Overall, our
data support the applicability of high-density peptide microarrays for the rapid identifica-
tion and mapping epitopes that could be readily translated into novel and useful tools for
diagnosis of Chagas disease.
Introduction
Chagas disease is a major health and economic problem in Latin America, for which no vac-
cine or appropriate drugs for large-scale public health interventions are yet available [1]. It is
caused by the protozoan parasite Trypanosoma cruzi, found throughout the Americas in a vari-
ety of wild and domestic mammalian reservoirs, and it is usually transmitted by infected
blood-sucking triatomine bugs. It is estimated that ~5.7 million people are currently infected
with T. cruzi and that up to 120 million individuals living in endemic areas in Latin America
are at risk of infection [2]. Chagas Disease remains the most important parasitic disease in the
Western Hemisphere, with an estimated disease burden, as measured by disability-adjusted
life-years, that is 7.5 times as great as that of malaria [2]. Increasing travel and immigration
have also brought the risk of T. cruzi infection into non endemic countries [3]. Several efforts
have successfully been undertaken to control transmission in Latin America, with a concomi-
tant decrease in the number of acute vector-borne infections [4]. However, humans can also
become infected with T. cruzi through the ingestion of tainted food and fluids, receipt of con-
taminated blood transfusion or organ transplantation, laboratory accidents, and from mother-
to-child during pregnancy/delivery [1,4]. The diagnosis of Chagas disease is challenging
because it is often asymptomatic in its acute phase and evolves into a chronic stage in which
the disease presents diverse clinical forms [1]. In addition, and due to a major decline in para-
sitemia during the chronic phase, the detection of T. cruzi in blood samples by direct examina-
tion, hemoculture, or xenodiagnosis is difficult and time-consuming. Several PCR-based
procedures have been reported that, although highly specific, present suboptimal sensitivity
and require technological expertise and specialized expensive laboratory equipment [5]. In this
framework, detection of anti-T. cruzi antibodies remains the most effective method for dem-
onstrating direct exposure to the parasite [6]. At present, the most widely used serologic meth-
ods are indirect hemagglutination assay (IHA), indirect immuno-fluorescence assay (IIF),
and enzyme-linked immunosorbent assay (ELISA) using total parasite homogenates or semi-
purified antigenic fractions [7]. Despite their satisfactory performance, these tests show varia-
tions in their reproducibility and reliability that can be attributed to poor standardization of
the reagents or intrinsic variability of immune responses in patient populations [8–10]. In the
absence of a single reference test showing 100% specificity and sensitivity, the current
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guidelines developed by the World Health Organization advise the use of two serologic tests
for reaching a conclusive diagnosis. In the case of ambiguous or discordant results, diagnosis
using a third technique should be conducted. In addition, there are other still unmet needs
and gaps such as access to diagnostics in point-of-care sites for neglected populations [11,12],
as well as development of much needed tests for early identification of congenital transmis-
sion; rapid assessment of drug treatment efficacy or prognostics tests for disease progression
[10,13].
Recombinant DNA and peptide synthesis technologies historically allowed the production
and one-step purification of large amounts of T. cruzi immunodominant antigens [14]. How-
ever, several studies showed that the use of single antigens in an assay did not confer the sensi-
tivity required for a diagnostic test [14,15], which prompted the development of tests based on
combinations of antigens[16,17], some of which were evaluated in multicenter trials and are
commercially available [18–20]. Synthetic peptides are advantageous for diagnostic applica-
tions because they are: i) well defined (ease of quality control), ii) easily produced in large
amounts, ii) highly pure and often cost-saving if compared to the production of natural or
recombinant antigens in vitro [21]; and iv) also chemically stable (can be stored lyophilized or
dessicated and tend to be stable for several years).
Short synthetic peptides spanning linear B-cell epitopes can also be used in serodiagnostic
applications to increase specificity (that is, decrease the number of false positives) by replacing
the use of whole protein antigens, therefore avoiding the display of unnecessary sequences that
may lead to ‘false positive’ results. Specificity is a critical issue in serodiagnosis of Chagas Dis-
ease, where most reagents present cross-reactivity against other co-endemic parasites such as
Leishmania spp. [18,21]. Peptide sensitivity, on the other hand can be increased using more
densely presented immunoreactive epitopes (i.e. by creating a synthetic poly-epitopic mole-
cule) or by combining multiple antigenic peptides in a single multiplex-assay [21–23]. A num-
ber of studies described the use of short peptides, containing either one or several epitopes for
diagnosis of Chagas disease and other infectious diseases [23–34].
Recently, we have prioritized a number of candidate diagnostic targets from the genome of
T. cruzi [35] and conducted a large-scale screening of parasite B-cell linear epitopes using
high-density peptide microarrays [36]. This approach led to the identification of several hun-
dred novel epitopes associated to chronic Chagas Disease, from which we selected 30 for fur-
ther characterization. In this paper, we describe their diagnostic evaluation in ELISA format
using a large panel of serum samples. In addition, and following an in silico-guided antigen
combination strategy, we developed a proof-of-principle diagnostic kit based on these reactive
peptides.
Materials and methods
Peptide selection
More than 2,000 candidate serodiagnostic peptides were previously identified by our group
using a T. cruzi/Chagas HD peptide microarray [36]. To guide the selection of a subset of pep-
tides for further serological characterization, a filtering strategy was conducted, as follows.
First, peptides with serodiagnostic potential (high signal-to-noise ratio in the microarray
experiments) were mapped to 187 distinct antigenic protein regions (stretches of adjacent pep-
tides in a protein sequence). These antigenic regions may contain either a single B-cell linear
epitope or, in some cases, a limited number of partially overlapping epitopes [37]. Next, anti-
genic regions were grouped into clusters of sequence-related peptides, in such a way that pep-
tide sequences sharing stretches of 7 or more identical amino acids were put into the same
cluster. We reasoned that peptides within a cluster may be both sequence and also likely
Next-generation ELISA diagnostic assay for Chagas Disease
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antigenically related, whereas peptides from different clusters may likely represent the targets
of different antibody specificities. From each cluster only a single antigenic region was kept
(the one with highest microarray average seroreactivity). After this filter 95 unique antigenic
regions were obtained (non-redundant, non-similar). From this set we selected 30 peptides
from the top of the ranking for further characterization (the most reactive 15-mer from each
antigenic region was selected). To minimize possible bias in our selection, the number of
selected peptides from overrepresented sequences such as those from the mucin-associated
surface protein (MASP) family [38] and from previously known antigens with mapped epi-
topes [24,39–43] was limited to 3 and 4, respectively. Sequence and features of our final set of
synthetic peptides is summarized in Table 1.
Peptides in Table 1 were synthesized and used in ELISA assays as described below (see also
Results) to screen for reactivity against Chagas positive and negative (control) samples. Once
we obtained a first matrix of reactivity of peptides vs individual serum samples, we applied the
EpiSelect algorithm to guide the selection of sets of peptides for the formulation of multiepi-
tope assays. Implementation of the algorithm has been described [47], but briefly the algorithm
aims to find the smallest selection of peptides (epitopes) that in concert maximizes the cover-
age (reactivity) against a given set of subjects. The input to the algorithm was the matrix of
Table 1. Sequence and features of synthetic peptides evaluated in this work. Bibliographic references are provided for the most relevant publication
where the corresponding epitope has been mapped, or the protein has been validated as a human antigen.
Peptide Protein Description Peptide sequence Reference
p1 TcCLB.507071.20 mucin-associated surface protein (MASP) LQVAGIKTTTATTGDS This work
p2 TcCLB.506401.320 60S ribosomal protein L7a, antigenic protein AKPAAKPAAKPAAKP [35]
p3 TcCLB.506973.30 mucin-associated surface protein (MASP) EKQQQSDEAQVQQHQ This work
p4 TcCLB.511727.290 RNA-binding protein PASKPAAKPAAKAPA This work
p5 TcCLB.507083.109 hypothetical protein, conserved WFEREVDGHDFIREH This work
p6 TcCLB.507071.170 mucin TcMUCII TTNAPSRLREIDGSL [44]
p7 TcCLB.509793.50 hypothetical protein, conserved KLGKSVGLTAALSPR This work
p8 TcCLB.510101.430 40S ribosomal protein S21 GRDAPQARKQQGRNE This work
p9 TcCLB.511679.10 mucin TcSMUGS EGQYDAADVEAGDGP This work
p10 TcCLB.506391.30 EF-hand protein 5 LMTREVDDTMADELR [20]
p11 TcCLB.511529.80 kinetoplast DNA-associated protein ALRVSPYSIFLQELA This work
p12 TcCLB.511633.79 microtubule-associated protein EEEEDVGPRHVDPDH [45]
p13 TcCLB.506961.25 trans-sialidase DSAKGKATGSSAGED This work
p14 TcCLB.511287.120 40S ribosomal protein S2 RDPTDEHSDFLTMGS This work
p15 TcCLB.506563.40 beta tubulin PTGTYQGDSDLQLER This work
p16 TcCLB.504159.10 hypothetical protein, antigenic protein n126 TSAPAAGGFGSATTT [35]
p17 TcCLB.511633.79 microtubule-associated protein PTTSARRLRTRTGPL [45]
p18 TcCLB.510421.330 hypothetical protein, conserved ILDRFLAAAMDKVFT This work
p19 TcCLB.506989.190 heat shock protein 90, putative (LPG3) PVDNDGDESSDKEDA This work
p20 TcCLB.511633.79 microtubule-associated protein VDPSAYKRALPLEEQ [45]
p21 TcCLB.509157.120 hypothetical protein, conserved SGAVPEGEEYPTEAE [46]
p22 TcCLB.507071.100 mucin-associated surface protein (MASP) SEREDDEENDEEEDG This work
p23 TcCLB.511727.290 RNA-binding protein GAAKAPAPKAAAPAP This work
p24 TcCLB.511671.50 hypothetical protein, antigenic protein n96 AKPPAESPFKSVFGA [35]
pc1 TcCLB.508831.140 B13 / Ag2 / CA-2 / PEP2 APFGQAAAGDKPSPF [41]
pc2 TcCLB.509149.40 Ribo L19 AAAPAKAAAAPAKAA [24]
pc3 TcCLB.505975.20 TcD / Ag13 EPKSAEPKPAEPKSA [45]
pc4 X57235 Trans-sialidase (SAPA) TPADSSAHSTPSTPA [43]
https://doi.org/10.1371/journal.pntd.0005972.t001
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peptide reactivity values determined by ELISA, encoded as z-scores defined as the number of
standard deviations above background. Positive peptides were defined using a z-score thresh-
old of 3.
Synthetic peptides and BSA conjugation
Synthetic peptides were purchased from Schafer-N (Copenhagen, Denmark). Peptides were
synthesized using standard FMOC chemistry, purified by HPLC (> 90% purity) and charac-
terized by mass spectroscopy. A C-terminal cysteine residue was included in all peptides for
conjugation to maleimide-activated BSA. An additional amino acid residue (leucine) was
added at the N-terminus of peptide p1, to avoid the partial deamination associated with an
N-terminal glutamine [48]. Lyophilized peptides were resuspended in sterile-filtered water
(Sigma Product w3500), and conjugated to maleimide-activated BSA (mBSA, Sigma-Aldrich
Product B7542) according to the manufacturer’s protocol, using a molar ratio of 35:1 peptide
to mBSA [49]. Peptide-mBSA conjugates were stored in 50% glycerol at -20˚C until use. Pep-
tides that failed to solubilize under these conditions were discarded for the analysis.
Human serum samples, samples size and error estimation
Human serum samples from T. cruzi-infected patients used in this study were obtained from
the Laboratorio de Enfermedad de Chagas, Hospital de Niños "Dr. Ricardo Gutierrez"
(HNRG, Buenos Aires, Argentina) (n = 80). Human serum samples from patients with Ameri-
can Tegumentary Leishmaniasis (ATL) used in this study were obtained from the Instituto de
Patologı´a Experimental, Universidad Nacional de Salta (IPE, Salta, Argentina) (n = 19). All
procedures were approved by the research and teaching committee and the bioethics commit-
tee of both institutions, and followed the Declaration of Helsinki Principles. Written informed
consent was obtained from all individuals (or from their legal representatives), and all samples
were decoded and de-identified before they were provided for research purposes. Chagasic
patients were in the asympomatic chronic stage of the disease without cardiac or gastrointesti-
nal compromise (age range: 11 to 51 years old, median age: 20). Serum samples were collected
from clotted blood obtained by venipuncture and analyzed for T. cruzi-specific antibodies
with the following commercially available kits: ELISA using total parasite homogenate (Wiener
lab, Argentina) and IHA (Polychaco, Buenos Aires, Argentina). ATL patients were diagnosed
using a combination of techniques: direct observation of parasites (amastigotes) on smears of
dermal scrapings; a test of delayed-type hypersensitivity (Montenegro skin test); and a clinical
assessment (see [50]). The negative panel was composed of samples from healthy, non-infected
individuals that gave negative results in the aforementioned tests, and were obtained either
from the blood bank “Fundacio´n Hemocentro Buenos Aires” (FHBA Buenos Aires, Argen-
tina) (n = 82) or from IPE (n = 18). Samples from FHBA were also negative for HIV, Hepatitis
B, Hepatitis C, HTLV I and II, Treponema pallidum (syphilis) and for Brucelosis (Huddlesson
test).
To calculate the minimum sample size required to estimate sensitivity or specificity for a
specified interval of confidence and precision under a normal approximation, we used the fol-
lowing formula:
n ¼
Z2 P^ ð1   P^Þ
d2
Where Z is the z-score from a standard normal distribution (e.g. 1.96 for a 95% confidence
interval), P^ is the pre-determined (guess) value of sensitivity (or specificity) based on previous
experience/judgment, and d is the required precision [51]. Therefore, for Z = 1,96 (95% CI),
Next-generation ELISA diagnostic assay for Chagas Disease
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P^ = 0.99, and d = 0.05 (5% error), the estimated sample size is 73. Therefore 73 is the minimum
number of Chagas positive samples (to estimate sensitivity) and Chagas negative samples (to
estimate specificity).
ELISA assays and statistical analysis
Microplates containing 96 or 384-wells (Thermo Scientific ImmunoPlates, MaxiSorp) were
coated overnight at 4˚C with 100 ng/well of peptide-mBSA or with different peptide mixtures
(80 ng/well of each one) in PBS pH 7.4. Blank signal was determined using mBSA-coated
wells. After 4 washings with TBS-T (50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.05% (v/v)
Tween20), the plates were blocked for 1 h at room temperature with 100 μl/well of assay buffer
(3% (w/v) skimmed milk in TBS-T). The plates were washed and incubated for 1 h with
human sera diluted as indicated (1:100 or 1:10) in assay buffer at room temperature. Optimiza-
tion of the assay conditions was performed by a checkerboard titration analysis using 10 ng or
80 ng of peptide-mBSA, and different dilutions of secondary antibody (peroxidase-conjugated
goat anti-human IgG antibodies (Sigma-Aldrich, St Louis, MO) (1:5,000; 1:10,000; 1:20,000
and 1:80,000). After washings, 100 μl of secondary antibody diluted as indicated (1:10,000 for
assays using a single peptide per well, or 1:80,000 for multiepitope assays) in assay buffer were
added to each well and incubated for 1 h at room temperature. Following additional washings
with TBS-T, the reaction was developed with tetramethylbenzidine for 15 min (TMB, Sigma-
Aldrich, St Louis, MO) and stopped by addition of 0.2 M sulphuric acid. Absorbance values
were measured at 450 nm in a microplate absorbance reader (FilterMax F5 Multimode, Molec-
ular Devices, Sunnyvale, CA, USA). All serum samples were tested in duplicate. Values were
averaged and blank-corrected.
Data analysis
The same 16 serum samples from healthy blood donors were tested in each ELISA plate. The
cut-off value was determined for each peptide and for each plate using the mean of the control
blood donor samples plus 3 SD (the cut-off was set accounting for multiple-hypothesis test-
ing). For each peptide or peptide mixture, standardized reactivity scores (z-scores) and the
diagnostic analytical characteristics of sensitivity, specificity and AUC (Area under the ROC–
Receiver Operating Characteristic–curve, as a performance metric) were calculated. Reagent
sensitivity was calculated as the number of positive subjects (i.e. infected patients samples that
were reactive against a particular peptide) over the total number of infected subjects tested;
specificity was calculated as the number of negative subjects (non-infected control subjects
that were seronegative against a particular peptide) over the total number of non-infected con-
trol subjects tested and AUC was calculated using the from the z-scores of infected subjects
and non-infected subjects. For receiver operating characteristic (ROC) analyses [52], the
results were expressed as the percentage of reactivity of the mean absorbance at 450 nm of the
positive reference control serum included in each assay run. The Mann-Whitney test and
ROC analysis were performed using the GraphPad Prism software (version 6 for OSX; San
Diego, CA, USA) or ROCR R package [53].
Results
Diagnostic performance of selected peptides in ELISA format
Based on our previous screening of serodiagnostic peptides for Chagas Disease using HD pep-
tide microarrays [36], 30 peptides were selected for further serological characterization and
downstream validation. The strategy for selection of these peptides is outlined in Fig 1 (see
Next-generation ELISA diagnostic assay for Chagas Disease
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also Methods), and essentially was guided to select a non-redundant set of peptides showing
the highest antibody-binding signal in any array. After removing 3 peptides that showed solu-
bility problems, the remaining 27 peptides were coupled to a carrier protein (mBSA) and
assayed in ELISA format against a sera panel of 62 chronically infected Chagasic patients and
16 healthy controls. Initially, all human sera were tested at 1:100 dilutions. The panel of pep-
tides included 16 peptides corresponding to previously uncharacterized T. cruzi proteins
(novel antigens) that emerged during our screening [36], 7 peptides representing novel epi-
topes in previously characterized B-cell antigens and 4 peptides corresponding to previously
known linear B-cell epitopes, which were used as positive controls (see Table 1 and S1 Fig).
We also included in our panel an additional peptide (p17) as an internal negative control.
Although belonging to a validated T. cruzi antigen [54], this peptide was derived from a pro-
tein region that showed consistently very low signal in all microarray replicates.
Diagnostic sensitivity, specificity and AUC values for each peptide are shown in Table 2
(complete data available in S1 Table). The diversity of reactivities in the collection of sera sam-
ples when assayed against individual peptides is also evident when visualizing the data in the
form of a heatmap plot (available in S2 Fig). As shown, promising diagnostic performances
were observed for most of the assayed peptides. Sensitivity values ranged from 30–92% (>50%
in 22 out of 27), and specificity values were extremely high, which is consistent with our
screening strategy [36]. In this context, it is worth noting that sensitivity values of all individual
T. cruzi antigens described so far and proposed and/or included in serodiagnostic tests ranged
from 80–99% [14].
Overall, and as previously reported for the TSSA antigen [37], a strong correlation between
assays in the standard ELISA format and in microarray format was observed for each peptide
(Table 1), thus providing additional validation and support for the use of HD-peptide arrays
for discovery of new serology-based biomarkers.
Fig 1. Flowchart showing the strategy for peptide selection.
https://doi.org/10.1371/journal.pntd.0005972.g001
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Extended evaluation of diagnostic specificities of top-ranked peptides
We further evaluated the diagnostic specificity of the 16 best performing peptides (see Table 1)
by using an extended panel of 61 control sera obtained from healthy subjects (Chagas-negative
samples). As before, individual peptides coupled to mBSA were assayed in ELISA format.
Diagnostic specificities and ROC-AUC were re-calculated for each peptide (top entries in
Table 2). The average specificity was 97.23% and in all cases specificities > 95% were observed.
Notably, most of the positive responses observed in this expanded set of Chagas-negative sam-
ples correspond to only 3 of the 61 sera samples tested. These samples (also negative for the
highly-sensitive trans-sialidase inhibition assay [55]) were highly reactive against more than
half of the peptides (12, 11 and 9 peptides each, see S1 Table in the ‘Additional negative sera’
section), suggesting a broad and yet-to-be explained cross-recognition towards T. cruzi-
derived sequences. If these Chagas-negative serum samples were removed, specificity values of
our peptides would increase up to an average 98.5%.
A novel multiepitope diagnostic method for Chagas Disease
Based on the results described above, we undertook an in silico-guided approach to design a mul-
tiplex assay with improved diagnostic performance. Using ELISA data from individual peptides,
Table 2. Diagnostic performance of selected peptides in ELISA format. Peptides are sorted per decreasing sensitivity.
Peptide Avg signal (pepchips) Sensitivity (n = 62) Specificity ROC AUC
pc1 46,23 91,98 98.36 (n = 61) 0,99
pc2 35,22 90,31 96.72 (n = 61) 0,98
p7 17,19 84,06 96.72 (n = 61) 0,94
p11 13,43 84,06 95.1 (n = 61) 0,96
p16 10,89 83,85 98.36 (n = 61) 0,94
p1 64,57 80,94 98.36 (n = 61) 0,94
p19 7,39 80,94 95.1 (n = 61) 0,95
p5 26,15 80,63 98.36 (n = 61) 0,96
pc3 13,66 78,96 100 (n = 61) 0,97
pc4 0,08 77,08 95.1 (n = 61) 0,94
p12 11,73 76,15 96.72 (n = 61) 0,94
p24 4,45 74,17 100 (n = 61) 0,95
p6 23,56 69,06 98.36 (n = 61) 0,9
p21 6,87 65,94 95.1 (n = 61) 0,88
p18 7,63 64,79 96.72 (n = 61) 0,91
p13 11,53 60,42 96.72 (n = 61) 0,88
p15 11,1 59,58 100 (n = 16) 0,81
p2 50,61 57,81 100 (n = 16) 0,88
p4 26,52 56,04 100 (n = 16) 0,88
p10 13,78 54,79 100 (n = 16) 0,88
p3 31,06 53,65 100 (n = 16) 0,8
p20 4,3 50,1 100 (n = 16) 0,83
p8 16,7 45,83 93,8 (n = 16) 0,76
p14 11,22 45,73 93,8 (n = 16) 0,76
p22 6,65 32,4 100 (n = 16) 0,72
p23 5,85 30,42 100 (n = 16) 0,77
p9 15,68 29,06 93,8 (n = 16) 0,73
p17 0 3,23 100 (n = 16) ND
https://doi.org/10.1371/journal.pntd.0005972.t002
Next-generation ELISA diagnostic assay for Chagas Disease
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005972 October 9, 2017 8 / 19
we applied the EpiSelect algorithm [47] (see Methods) to identify several optimal (minimal) vir-
tual peptide sets that in concert provided maximal coverage of the analyzed subjects. This analysis
was performed after removing data from the 9 serum samples that were previously used in micro-
array experiments, to avoid optimistically biased results. The analysis performed on the tested
peptides and 53 Chagas-positive subjects showed that 3 peptides were enough to reach a theoreti-
cal sensitivity of 100% (Fig 2). Data used for this analysis is available in S1 Table. The optimal set
was composed by peptides {pc1, pc2, and p6}, resulting in an average of 2.51 reactive peptides per
subject, closely followed by the peptide set {pc2, p11, and p6} with an average of 2.43 reactive pep-
tides per subject. The reactivity patterns for these sets are shown in Fig 2 and S1 Table. Interest-
ingly, at least 1 of the 3 novel peptides p6 (as in Fig 2), p2 or p8 (alternatives) would be required to
achieve a sensitivity of 100% with a 100% specificity (see also S1 Table).
Other peptides such as p5, p7, p11, p12, p16, p19 and p24 also displayed excellent diagnostic
characteristics, with individual high sensitivity (> 70%) and specificity (up to 95%). Hence,
these peptides can be eventually incorporated into the multiplex design to increase its robust-
ness (for example, to increase the number of reactive peptides per subject).
Based on these analyses, we prepared and tested a number of multi-epitope peptide combi-
nations in ELISA format against an extended panel of sera from chagasic (positive) and healthy
(negative) subjects. One such combination {pc1, pc2, pc3, p6, p13}, was tested against 22 posi-
tive and 24 negative serum samples and gave a diagnostic sensitivity of 72.7% and a specificity
of 91.7%. Following the same methodology (S1 Table), we tested a slightly different formula-
tion of peptides (pc1, pc2, p6, p7 and p24) against an increased number of sera samples (53
Chagas-positive and 31 Chagas-negative) obtaining an improved performance, with a sensitiv-
ity of 92.45% and a specificity of 93.55%.
Finally, with the aim of obtaining a peptide combination with enhanced robustness, we re-
analyzed the reactivity profile of each individual serum sample (S1 Table) against our panel of
peptides, and identified a few Chagas positive subjects that gave low or even negative reactivity
to many peptides. From this analysis, we identified peptides that would theoretically maximize
the sensitivity of the multiplex assay, despite not showing the best possible coverage of our sub-
ject (sera) collection. Thus, we arrived at a high performance multi-epitope formulation of
seven peptides {pc1, pc2, pc3, p6, p7, p13, and p24}. To validate this final formulation, we
increased the amount of coated peptide to 80 ng of each peptide per well and the serum con-
centration to 1:10. After these modifications, the performance of this formulation, when tested
against 82 Chagas-positive and 80 Chagas-negative sera samples gave a sensitivity of 96.34%
and a specificity of 100%, with an AUC value of 0.9974 (Fig 3).
Fig 2. Reactivity pattern of example optimal peptide subsets. Two peptide combinations were created using the EpiSelect algorithm to achieve a
theoretical 100% sensitivity, based on data from the individual assays in S1 Table (53 Chagas positive samples, 27 peptides). The figure shows positive
(green) and negative (red) results for each combination of peptide and subject. The cumulative sensitivity is also indicated. For each set, the bottom row
displays the cumulative number of positive results for each subject.
https://doi.org/10.1371/journal.pntd.0005972.g002
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We have also assessed the performance of this multiepitope formulation against a panel of
19 sera from subjects with positive diagnosis for American Tegumentary Leishmaniasis (see
Methods), and another 18 negative (control sera) from the same endemic region. Only a single
(negative) subject gave a positive response in our multiepitope assay (Fig 3C). Except for this
Fig 3. Diagnostic performance of the final multiepitope formulation. A) Scatter plot showing the
distribution of ELISA raw signal obtained from sera samples of Chagas-positive (green circles) and healthy
subjects (red squares). Statistical significance (*) p<0.0001, Mann-Whitney test. Green empty circles in the
left scatter plot represent those within 3 standard deviations of the average signal of healthy controls. B)
Receiver Operating Characteristic curve and statistics for the analysis. C) Scatter plot showing the distribution
of ELISA raw signal obtained from Leishmaniasis-positive (green cirles) and Leishmaniasis-negative subjects
from the same co-endemic region (red squares). Empty circles represent data points that fall at >3 SD from
their respective distributions.
https://doi.org/10.1371/journal.pntd.0005972.g003
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case, the observed absorbance in the ELISA assays was nil. The specificity of the multiepitope
formulation for this panel was 97.30%, with an overall specificity (considering all negative
samples from all panels) of 99.15%. Table 3 summarizes the performance of this combination
of peptides. This therefore represents a highly promising novel multiepitope formulation for
the diagnosis of Chagas Disease.
Discussion
Serological diagnostics methods for infectious diseases have usually evolved from first-genera-
tion lysate-based reagents. Through time, more defined formulations of diagnostic reagents
have followed. Second-generation diagnostic kits based on purified antigenic fractions or
third-generation kits based on recombinant proteins are now in widespread use. To develop
new diagnostic tools that are simple and have few manipulation steps, one of the central
aspects that currently limits the suitability of diagnostic kits is the need to produce, prepare
and purify the antigens, along with the corresponding quality control. Short synthetic peptides
can be produced cheaply in large quantities, and are chemically stable and amenable for long-
term storage. Synthetic peptides have been already tested in a wide range of diagnostic applica-
tions and proved valuable for diagnosis of viral, bacterial, parasitic and autoimmune diseases
[21,30–34]. Therefore, fourth-generation diagnostic kits based on well-defined peptidic anti-
gens are now within reach.
Here we present a next-generation diagnostic formulation for Chagas Disease based on
short peptides. Significant efforts have been invested by various groups over time to identify
and test antigenic peptides for serodiagnosis of Chagas Disease, some of which displayed
promising analytical characteristics. For example, peptides Ag2/B13/Pep2, TcD/Ag13, TcE
and TcLo1.2, have been combined to create a multi-epitope recombinant neo-protein of excel-
lent performance [24], and peptides from the cytoplasmic repetitive antigen (CRA)/Ag30 and
flagellar repetitive antigen (FRA)/Ag1 [54] have been recently shown to present good specific-
ity and sensitivity [56].
The advent of novel high-throughput approaches spawned by the post-genomic era is start-
ing to impact on the discovery of new biomarkers and the development of diagnostic tools for
a number of important pathogens [10]. We have recently showed the utility of a fast approach
to screen for new T. cruzi antigens that is based on high-density peptide microarrays [36]. The
advantage of this platform is that it allows to identify antigens and at the same time obtain a
fine mapping of their linear epitopes. Using this strategy we have identified and mapped the
epitopes of>90 novel T. Cruzi antigens [36].
As a followup of this first screening for peptidic antigens, we provide here an extensive sero-
logical characterization of 27 peptides, 18 of which represent novel epitopes that were mapped
using our strategy, or represent recently discovered antigens but for which no fine epitope
mapping was yet available (see Table 1). For example, even though the trans-sialidase/SAPA
antigen (accession number X57235, TcCLB.509495.30 is the most similar genome locus tag)
has been known for quite some time, peptide p13 (also annotated as ‘trans-sialidase’) is not
Table 3. Summary of performance of the final multiepitope combination.
Multi-epitope combination pc1, pc2, pc3 + p6, p7, p13, p24
Sensitivity (True Positive Rate) 96.34%
Specificity (True Negative Rate) 99.15%
Positive Predictive Value 98.75%
Negative Predictive Value 97.47%
https://doi.org/10.1371/journal.pntd.0005972.t003
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derived from the originally described antigen, but from another member of the superfamily
(TcCLB.506961.25) with only 29% identity to the original trans-sialidase/SAPA. Therefore,
p13 is a new/novel antigen and epitope that bear no resemblance to any of the mapped epi-
topes already described [43,57]. Similarly, even though the proteins encoded by the genes
TcCLB.511633.79 (microtubule-associated protein), or TcCLB.506391.30 (EF-hand protein 5)
were already described and used as antigens [20,46], this is the first time that their fine mapped
epitopes are tested for diagnostic purposes. Other peptides such as p16, p7, p11 and p19 are
part of proteins that have been identified as potential antigens [35] but with no other serologi-
cal evidence before our microarray experiments. Peptide p1, on the other hand, was derived
from a member of the Mucin-Associated Surface Protein (MASP) family [38], which is a large
family of genes which were shown recently to be the target of the adaptive immune response
in an animal model of infection [58]. The MASP protein encoded by gene TcCLB.507071.20
was selected from the genome, as part of an effort to obtain a detailed characterization of the
antigenicity and epitopes of this gene family in human infections [59]. Peptide p6 contains a
slightly different version of the sequence TTRAPSRLREID, which has been identified as the
major and conserved linear B-cell epitope included within the otherwise highly polymorphic
TcMUCII family of T. cruzi proteins [44,60]. Whereas peptide p2 is a novel epitope from a
putative 60S ribosomal protein L7a, that we have also previously identified as a potential anti-
gen [35].
Using a panel of Chagas-positive and negative (control) samples, we performed a thorough
serological characterization of the selected peptides. This allowed us to obtain a relatively large
matrix of ELISA responses for all peptides against individual serum samples. This led us to
identify a number of peptides with promising diagnostic potential, such as peptides p1, p7,
p11, p16 and p19, which presented sensitivities above 80%, with no false positive responses in
the first evaluation using a small panel of 16 sera, and only a few false positive responses (with
specificities from 96.5% to 100%) in a second evaluation using a larger panel of sera. These sen-
sitivities are similar to those originally reported in the first characterizations of validated sero-
diagnostic antigens such as TcD (95% for chronic subjects [61]) and SAPA (10% for chronic
subjects, 90% for acute infection [62]), which were later improved when developed into a mul-
tiantigen diagnostic reagent (e.g. the Chagatest kit of Wiener Labs that includes these antigens
claims a sensitivity of 98.8%[63]). Hence, even if some peptides displayed sensitivities that
were not very high when assessed singly, they were high enough as to keep them under consid-
eration for development of an assay based on combinations of peptides.
The matrix of ELISA responses was then used to guide the rational formulation of a multie-
pitope diagnostic reagent using a well-defined algorithm for the inclusion of peptides. The first
combinations tested did not achieve a significantly high performance, even if the theoretical
prediction (Fig 2) would suggest otherwise. One reason for this is that even though the input
to the EpiSelect algorithm included the level of response of each subject against each peptide
(represented as the number of standard deviations above negative controls), the effect of com-
bining peptides produced a higher background signal that was not predicted by the algorithm.
Another reason was the inclusion in our panel of Chagas-positive sera of several samples with
moderately low antibody titers overall (see for example the 9 sera grouped in the bottom
branch in S2 Fig). Despite these pitfalls, the detailed data present in this matrix was pivotal in
identifying peptides for inclusion in the final multiepitope formulation. The rationale for
inclusion of peptides was the ability of a given peptide (as observed in the matrix) to potentially
overcome a negative response for a given serum sample. For example, peptides p6 and p2, fol-
lowed by p11 represented an optimal complement of the two best performing peptides, pc1
(from the antigenic repeat of the CA-2/B13 antigen Ag2) and pc2 (the serodiagnostic epitope
TcE) for diagnosis. Also, peptide p13 when combined with peptides pc1 and pc2 was one of
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the few peptides that provided relatively high signal in the ELISA assay against the group of
sera with relatively low overall responses. The fact that we could consistently increase the per-
formance of each combination upon following this rationale shows the usefulness of this
approach.
Interestingly, all peptides in the final multiepitope formulation are highly conserved (see S1
Text). A sequence similarity search across available complete genomes (e.g. those from the
CL-Brener [64] and Sylvio X10 [65] strains using BLASTP) or from draft assemblies (Tula cl2,
Esmeraldo cl3, Dm28c or JRcl4 in the TriTrypDB resource [66], release 30 from February
2017, using TBLASTN) shows that all peptides are highly conserved across strains representing
different evolutionary lineages of the parasite (TcI, TcII, TcV, TcVI).
The observed diagnostic performances for all peptides and peptide combinations tested
were very promising, particularly considering that all assays were based on short synthetic pep-
tides. Our final best performing multi-epitope combination was based on a combination of
seven antigenic peptides. With an equimolar mixing of peptides, we attained a very high
(>96%) level of sensitivity and specificity. These are highly promising values for a first optimi-
zation attempt; the final ELISA assay/formulation could be indeed further improved using dif-
ferent blocking reagents, coupled detection system and, most importantly, by adjusting the
relative concentration of different peptides in the final mixture.
Analysis of potential cross-reactivity with other co-endemic diseases and pathogens is
essential to validate any diagnostic reagent. In the case of Chagas Disease, cross-reactivity
against infections with Leishmania species is a particular concern [67]. We have included a
panel of serum samples from confirmed cases of tegumentary leishmaniasis from the northern
province of Salta, Argentina to assess the performance of our formulation. This also gave us
the opportunity to improve the assessment of specificity by analizing a paired set of negative
(control) samples (chagas-negative and leishmaniasis-negative) from the same endemic
region. From a set of 37 of these samples which were negative for Chagas Disease, only one
gave a positive cross-reactive response (Fig 3). Although this highlights the need to perform a
more extensive characterization of this cross-reactive sample (e.g. against our complete panel
of peptides), and eventually revise the combination of peptides in our formulation, the current
multiepitope assay has a sufficiently high specificity at this stage (99.15%), comparable to other
commercially available kits [63] that can certainly be improved by optimization of the assay or
by replacing of cross-reactive peptides.
Besides the obvious attention to the diagnostic performance of the identified peptides, these
results serve to validate the use of high-density peptide microarrays as a fast screening plat-
form. The fact that all selected peptides gave positive responses against several Chagas-positive
subjects show that this technology can be trusted to rapidly identify and map epitopes of com-
plex pathogens. It is also worth mentioning here that there are about a hundred additional
antigenic regions within the signal range observed in the peptide microarray screening from
which these peptides were identified [36] and that await further serological characterization.
This observation, together with the fact that the microarray screening only covered ~3% of the
parasite proteome, show that there is still a large repertoire of Chagas-specific antibody speci-
ficities that remain serologically unexplored.
The results presented herein hence provide a novel, robust multi-epitope formulation as a
basis for the development of improved peptide-based serodiagnostics for Chagas Disease. In
contrast with chimeric DNA constructs that encode multiepitope recombinant proteins, the
fact that this diagnostic reagent is based on the combination of short peptides that can be syn-
thesized separately and easily formulated in a mix-and-match approach, means that it can be
improved successively over time with only a reasonable effort.
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Supporting information
S1 Fig. Antibody binding profiles of antigens showing the location of selected peptides.
The antibody binding profiles of antigens were derived from previously published data [36]
(ArrayExpress accession number E-MTAB-3008). Briefly, high-density peptide microarray
slides were assayed with purified immunoglobulins from healthy subjects (four pools of
samples labeled A-D, shown as dashed lines) or Chagas positive subjects (four pools of sam-
ples labeled A-D, shown as solid lines). Antibody binding profiles were reconstructed for
each of the selected antigens as described previously. Each plot in the figure shows the nor-
malized and smoothed signal profile for a single antigen (one per page). A different scale
may be used in each plot to best accommodate all peaks. The location of each the selected
peptides used in this study is shown in context with other antigenic regions in each antigen.
File: S1 Fig.
(PDF)
S2 Fig. Heatmap plot showing the pattern of reactivity of peptides against a panel of posi-
tive sera. Heatmap display of ELISA reactivity of each of the 27 peptides tested against a panel
of 62 positive sera samples. For the heatmap display the reactivity values (in the form of z-
scores above background) were transformed for clarity using a sigmoid function centered
around 3. Peptides and subjects were clustered using a hierarchical clustering algorithm (R,
hclust). A group of subjects showing moderately low ELISA reactivity across peptides has been
highlighted (see main text). File: S2 Fig.
(PDF)
S3 Fig. STARD flow diagram for studies reporting diagnostic accuracy.
(PDF)
S1 Table. Detailed results of ELISA assays. The spreadsheet workbook file contains a number
of worksheets with results from different ELISA assays: 1) all vs all ELISA results (N = negative;
P = positive) for each of the 27 peptides against 62 sera samples from chronically infected
(Chagas-positive) patients and 16 negative controls (healthy subject); 2) all vs all (z-scores)
contains the input matrix for the EpiSelect algorithm; 3) additional negative sera, ELISA
results for the best performing 16 peptides against an additional panel of 61 negative sera sam-
ples; 4) Formulation 1, ELISA results for the combination of peptides {pc1, pc2, pc3, p6, p13};
5) Formulation 2, ELISA results for the combination of peptides {pc1, pc2, p6, p7, p24}; 5)
Final formulation, ELISA results for the combination of peptides {pc1, pc2, pc3, p6, p7, p13,
p24}. File: S1 Table.
(XLSX)
S2 Table. STARD checklist for studies reporting diagnostic accuracy.
(PDF)
S1 Text. Conservation of peptides and epitopes across evolutionary Trypanosoma cruzi
evolutionary lineages. This supporting file contains information on the conservation of the
selected epitopes. We have tried to compile information from complete T. cruzi genomes from
different evolutionary lineages (Discrete Typing Units, DTUs). For each peptide (naming/
numbering follows Table 1), we provide a small multiple sequence alignment showing pres-
ence and conservation of the peptide in other strains/isolates. In the case of hybrid lineages
more than one representative sequence may have been included in the alignment. File: S1
Text.
(TXT)
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